Skip to main navigation

About

Our Story Executive Team Board of Directors

Technology and Platforms

Our Approach FasTCAR TruUCAR Manufacturing

Pipeline

Investors

Overview News & Events Financial Information Stock Information Corporate Governance IR Resources Contact Us

Publications

Overview
News & Events
Financial Information
Stock Information
Corporate Governance
IR Resources
Contact Us

News & Events menu

News Releases
Events & Presentations
Publications

Paper: Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL) (Abstract)

Source

confex.com

Paper: Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen …

Paper: Clinical Results of a Multicenter Study of the First-in-Human Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma (Abstract)

Source

confex.com

Paper: Clinical Results of a Multicenter Study of the First-in-Human Dual BCMA …

Eradication of T-ALL cells by CD7 targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management (Abstract)

Source

Clinical Cancer Research (aacrjournals.org)

Eradication of T-ALL cells by CD7 targeted universal CAR-T cells and initial te…

Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant (Abstract)

Source

Leukemia (nature.com)

Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post al…

CT052 - Clinical safety and efficacy study of TruUCAR™ GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) (Abstract)

Source

abstractsonline.com

CT052 - Clinical safety and efficacy study of TruUCAR™ GC027: The first-in-huma…

Shareholder Tools

Contact Us
Email Alerts
FAQs
RSS Feeds

Footer Links

Terms & Conditions
Privacy Policy
Contact Us
Careers

© 2021 Gracell All Rights Reserved.